{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:01:01Z","timestamp":1791414061430,"version":"4.3.3"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12325-026-03539-x","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T06:58:43Z","timestamp":1774335523000},"page":"1948-1966","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Insights on Medical Therapy for Uterine Fibroids: A Review"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5928-3565","authenticated-orcid":false,"given":"Giovanni","family":"Pecorella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5420-4277","authenticated-orcid":false,"given":"Andrea","family":"Morciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0515-1951","authenticated-orcid":false,"given":"Radmila","family":"Sparic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8859-0639","authenticated-orcid":false,"given":"Safak","family":"Hatirnaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0443-0572","authenticated-orcid":false,"given":"Mykhailo","family":"Medvediev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6940-7608","authenticated-orcid":false,"given":"Antonio","family":"Malvasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0614-8068","authenticated-orcid":false,"given":"Gianluca Raffaello","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8426-8490","authenticated-orcid":false,"given":"Andrea","family":"Tinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"3539_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60060868","author":"J Mici\u0107","year":"2024","unstructured":"Mici\u0107 J, Macura M, Andji\u0107 M, et al. Currently available treatment modalities for uterine fibroids. Medicina (Kaunas). 2024. https:\/\/doi.org\/10.3390\/medicina60060868.","journal-title":"Medicina (Kaunas)"},{"issue":"11","key":"3539_CR2","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1089\/jwh.2018.7076","volume":"27","author":"EE Marsh","year":"2018","unstructured":"Marsh EE, Al-Hendy A, Kappus D, Galitsky A, Stewart EA, Kerolous M. Burden, prevalence, and treatment of uterine fibroids: a survey of U.S. women. J Womens Health (Larchmt). 2018;27(11):1359\u201367.","journal-title":"J Womens Health (Larchmt)"},{"issue":"8","key":"3539_CR3","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1001\/jama.2016.9432","volume":"316","author":"JD Wright","year":"2016","unstructured":"Wright JD, Chen L, Burke WM, et al. Trends in use and outcomes of women undergoing hysterectomy with electric power morcellation. JAMA. 2016;316(8):877\u20138.","journal-title":"JAMA"},{"issue":"5","key":"3539_CR4","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1073\/pnas.1518752113","volume":"113","author":"M Mehine","year":"2016","unstructured":"Mehine M, Kaasinen E, Heinonen HR, et al. Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers. Proc Natl Acad Sci U S A. 2016;113(5):1315\u201320.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"3539_CR5","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1210\/endrev\/bnab039","volume":"43","author":"Q Yang","year":"2022","unstructured":"Yang Q, Ciebiera M, Bariani MV, et al. Comprehensive review of uterine fibroids: developmental origin, pathogenesis, and treatment. Endocr Rev. 2022;43(4):678\u2013719.","journal-title":"Endocr Rev"},{"key":"3539_CR6","volume-title":"Soft tissue sarcoma and leiomyoma - diagnosis, management, and new perspectives","author":"D Larra\u00edn","year":"2024","unstructured":"Larra\u00edn D, Prado J. New insights into molecular pathogenesis of uterine fibroids: from the lab to a clinician-friendly review. In: Abdul Hamid G, editor. Soft tissue sarcoma and leiomyoma - diagnosis, management, and new perspectives. London: IntechOpen; 2024."},{"issue":"6053","key":"3539_CR7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1126\/science.1208930","volume":"334","author":"N M\u00e4kinen","year":"2011","unstructured":"M\u00e4kinen N, Mehine M, Tolvanen J, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011;334(6053):252\u20135.","journal-title":"Science"},{"issue":"4","key":"3539_CR8","doi-asserted-by":"publisher","first-page":"e1517","DOI":"10.1210\/clinem\/dgz227","volume":"105","author":"M Ali","year":"2019","unstructured":"Ali M, Shaheen S, Ali Sabri N, Al-Hendy A, Yang Q. Activation of \u03b2-catenin signaling and its crosstalk with estrogen and histone deacetylases in human uterine fibroids. J Clin Endocrinol Metab. 2019;105(4):e1517\u201335.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"3539_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1067\/mob.2003.99","volume":"188","author":"DD Baird","year":"2003","unstructured":"Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100\u20137.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"3539_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.fertnstert.2023.01.022","volume":"119","author":"JG Katon","year":"2023","unstructured":"Katon JG, Plowden TC, Marsh EE. Racial disparities in uterine fibroids and endometriosis: a systematic review and application of social, structural, and political context. Fertil Steril. 2023;119(3):355\u201363.","journal-title":"Fertil Steril"},{"issue":"9252","key":"3539_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(00)03622-9","volume":"357","author":"EA Stewart","year":"2001","unstructured":"Stewart EA. Uterine fibroids. Lancet. 2001;357(9252):293\u20138.","journal-title":"Lancet"},{"key":"3539_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/IJWH.S51083","volume":"6","author":"AT Khan","year":"2014","unstructured":"Khan AT, Shehmar M, Gupta JK. Uterine fibroids: current perspectives. Int J Womens Health. 2014;6:95\u2013114.","journal-title":"Int J Womens Health"},{"issue":"6","key":"3539_CR13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/humupd\/dmw023","volume":"22","author":"J Donnez","year":"2016","unstructured":"Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update. 2016;22(6):665\u201386.","journal-title":"Hum Reprod Update"},{"key":"3539_CR14","doi-asserted-by":"publisher","first-page":"h4887","DOI":"10.1136\/bmj.h4887","volume":"351","author":"MA Lumsden","year":"2015","unstructured":"Lumsden MA, Hamoodi I, Gupta J, Hickey M. Fibroids: diagnosis and management. BMJ. 2015;351:h4887.","journal-title":"BMJ"},{"key":"3539_CR15","doi-asserted-by":"publisher","first-page":"16043","DOI":"10.1038\/nrdp.2016.43","volume":"2","author":"EA Stewart","year":"2016","unstructured":"Stewart EA, Laughlin-Tommaso SK, Catherino WH, Lalitkumar S, Gupta D, Vollenhoven B. Uterine fibroids. Nat Rev Dis Primers. 2016;2:16043.","journal-title":"Nat Rev Dis Primers"},{"key":"3539_CR16","first-page":"0814","volume":"2015","author":"A Lethaby","year":"2015","unstructured":"Lethaby A, Vollenhoven B. Fibroids (uterine myomatosis, leiomyomas). BMJ Clin Evid. 2015;2015:0814.","journal-title":"BMJ Clin Evid"},{"issue":"1","key":"3539_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.52054\/FVVO.15.1.059","volume":"15","author":"A Di Spiezio Sardo","year":"2023","unstructured":"Di Spiezio Sardo A, Ciccarone F, Muzii L, Scambia G, Vignali M. Use of oral GnRH antagonists combined therapy in the management of symptomatic uterine fibroids. Facts Views Vis Obgyn. 2023;15(1):29\u201333.","journal-title":"Facts Views Vis Obgyn"},{"issue":"4","key":"3539_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/17512433.2021.1900726","volume":"14","author":"M Ali","year":"2021","unstructured":"Ali M, Sara AR, Al Hendy A. Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Expert Rev Clin Pharmacol. 2021;14(4):427\u201337.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"3539_CR19","doi-asserted-by":"publisher","first-page":"662.e1","DOI":"10.1016\/j.ajog.2023.08.030","volume":"229","author":"A Al-Hendy","year":"2023","unstructured":"Al-Hendy A, Venturella R, Arjona Ferreira JC, et al. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids. Am J Obstet Gynecol. 2023;229(6):662.e1-.e25.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"3539_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/biolre\/iox094","volume":"97","author":"M Ali","year":"2017","unstructured":"Ali M, Al-Hendy A. Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids. Biol Reprod. 2017;97(3):337\u201352.","journal-title":"Biol Reprod"},{"issue":"6","key":"3539_CR21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1055\/s-0037-1606303","volume":"35","author":"K Fritton","year":"2017","unstructured":"Fritton K, Borahay MA. New and emerging therapies for uterine fibroids. Semin Reprod Med. 2017;35(6):549\u201359.","journal-title":"Semin Reprod Med"},{"key":"3539_CR22","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaa012","author":"MS Islam","year":"2020","unstructured":"Islam MS, Afrin S, Jones SI, Segars J. Selective progesterone receptor modulators-mechanisms and therapeutic utility. Endocr Rev. 2020. https:\/\/doi.org\/10.1210\/endrev\/bnaa012.","journal-title":"Endocr Rev"},{"issue":"4","key":"3539_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/GCO.0b013e32833b35a7","volume":"22","author":"ES Surrey","year":"2010","unstructured":"Surrey ES. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show? Curr Opin Obstet Gynecol. 2010;22(4):283\u20138.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"5728","key":"3539_CR24","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1126\/science.1112063","volume":"308","author":"CL Walker","year":"2005","unstructured":"Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science. 2005;308(5728):1589\u201392.","journal-title":"Science"},{"issue":"10-11","key":"3539_CR25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S0039-128X(00)00171-9","volume":"65","author":"T Maruo","year":"2000","unstructured":"Maruo T, Matsuo H, Samoto T, Shimomura Y, Kurachi O, Gao Z. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids. 2000;65(10\u201311):585\u201392.","journal-title":"Steroids"},{"issue":"3","key":"3539_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1055\/s-2007-1016336","volume":"14","author":"J Andersen","year":"1996","unstructured":"Andersen J. Growth factors and cytokines in uterine leiomyomas. Semin Reprod Endocrinol. 1996;14(3):269\u201382.","journal-title":"Semin Reprod Endocrinol"},{"issue":"5","key":"3539_CR27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.rbmo.2017.06.016","volume":"35","author":"S Vannuccini","year":"2017","unstructured":"Vannuccini S, Tosti C, Carmona F, et al. Pathogenesis of adenomyosis: an update on molecular mechanisms. Reprod Biomed Online. 2017;35(5):592\u2013601.","journal-title":"Reprod Biomed Online"},{"key":"3539_CR28","doi-asserted-by":"publisher","first-page":"173184","DOI":"10.1155\/2013\/173184","volume":"2013","author":"A Ciavattini","year":"2013","unstructured":"Ciavattini A, Di Giuseppe J, Stortoni P, et al. Uterine fibroids: pathogenesis and interactions with endometrium and endomyometrial junction. Obstet Gynecol Int. 2013;2013:173184.","journal-title":"Obstet Gynecol Int"},{"issue":"6","key":"3539_CR29","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1055\/s-0037-1607264","volume":"35","author":"A Al-Hendy","year":"2017","unstructured":"Al-Hendy A, Myers ER, Stewart E. Uterine fibroids: burden and unmet medical need. Semin Reprod Med. 2017;35(6):473\u201380.","journal-title":"Semin Reprod Med"},{"issue":"1","key":"3539_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/GRF.0000000000000171","volume":"59","author":"CB Bartels","year":"2016","unstructured":"Bartels CB, Cayton KC, Chuong FS, et al. An evidence-based approach to the medical management of fibroids: a systematic review. Clin Obstet Gynecol. 2016;59(1):30\u201352.","journal-title":"Clin Obstet Gynecol"},{"key":"3539_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/TCRM.S147318","volume":"15","author":"M Farris","year":"2019","unstructured":"Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G. Uterine fibroids: an update on current and emerging medical treatment options. Ther Clin Risk Manag. 2019;15:157\u201378.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"3539_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.fertnstert.2020.02.114","volume":"114","author":"J Donnez","year":"2020","unstructured":"Donnez J, Taylor HS, Taylor RN, et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. Fertil Steril. 2020;114(1):44\u201355.","journal-title":"Fertil Steril"},{"issue":"3","key":"3539_CR33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11154-021-09666-w","volume":"23","author":"S Vannuccini","year":"2022","unstructured":"Vannuccini S, Clemenza S, Rossi M, Petraglia F. Hormonal treatments for endometriosis: the endocrine background. Rev Endocr Metab Disord. 2022;23(3):333\u201355.","journal-title":"Rev Endocr Metab Disord"},{"key":"3539_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ph18010036","author":"S Patel","year":"2024","unstructured":"Patel S, Saxena B, Mehta P, Niazi SK. GnRH peptide antagonist: comparative analysis of chemistry and formulation with implications for clinical safety and efficacy. Pharmaceuticals (Basel). 2024. https:\/\/doi.org\/10.3390\/ph18010036.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"3539_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0303-7207(00)00291-4","volume":"166","author":"RE Felberbaum","year":"2000","unstructured":"Felberbaum RE, Ludwig M, Diedrich K. Clinical application of GnRH-antagonists. Mol Cell Endocrinol. 2000;166(1):9\u201314.","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"3539_CR36","doi-asserted-by":"publisher","first-page":"299","DOI":"10.14740\/jocmr6236","volume":"17","author":"JY Wang","year":"2025","unstructured":"Wang JY, Zhang Y, Ding J. Oral gonadotropin-releasing hormone antagonists in the treatment of endometriosis: advances in research. J Clin Med Res. 2025;17(6):299\u2013308.","journal-title":"J Clin Med Res"},{"issue":"4","key":"3539_CR37","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1056\/NEJMoa1904351","volume":"382","author":"WD Schlaff","year":"2020","unstructured":"Schlaff WD, Ackerman RT, Al-Hendy A, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020;382(4):328\u201340.","journal-title":"N Engl J Med"},{"issue":"3","key":"3539_CR38","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.fertnstert.2025.04.037","volume":"124","author":"WH Catherino","year":"2025","unstructured":"Catherino WH, Al-Hendy A, Zaim S, et al. Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2. Fertil Steril. 2025;124(3):523\u201333.","journal-title":"Fertil Steril"},{"issue":"6","key":"3539_CR39","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.fertnstert.2024.12.031","volume":"123","author":"J Donnez","year":"2025","unstructured":"Donnez J, Becker CM, Mangler M, et al. Linzagolix rapidly reduces heavy menstrual bleeding in women with uterine fibroids: an analysis of the PRIMROSE\u00a01 and 2 trials. Fertil Steril. 2025;123(6):1093\u2013100.","journal-title":"Fertil Steril"},{"key":"3539_CR40","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2147\/IJWH.S185023","volume":"11","author":"M Neri","year":"2019","unstructured":"Neri M, Melis GB, Giancane E, et al. Clinical utility of elagolix as an oral treatment for women with uterine fibroids: a short report on the emerging efficacy data. Int J Womens Health. 2019;11:535\u201346.","journal-title":"Int J Womens Health"},{"key":"3539_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.xfre.2023.02.002","author":"K Chwalisz","year":"2023","unstructured":"Chwalisz K. Clinical development of the oral gonadotropin-releasing hormone-antagonist elagolix. F&S Reports. 2023. https:\/\/doi.org\/10.1016\/j.xfre.2023.02.002.","journal-title":"F&S Reports"},{"issue":"12","key":"3539_CR42","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.jogc.2022.10.012","volume":"44","author":"R Niaz","year":"2022","unstructured":"Niaz R, Saeed M, Khan H, et al. Efficacy and safety of oral GnRh antagonists in patients with uterine fibroids: a systematic review. J Obstet Gynaecol Can. 2022;44(12):1279\u201388.","journal-title":"J Obstet Gynaecol Can"},{"issue":"2 Suppl","key":"3539_CR43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.xfre.2023.01.008","volume":"4","author":"FL Saleh","year":"2023","unstructured":"Saleh FL, Taylor HS. Clinical applications of gonadotropin-releasing hormone analogues: a broad impact on reproductive medicine. F&S Reports. 2023;4(2 Suppl):83\u20137.","journal-title":"F&S Reports"},{"issue":"9","key":"3539_CR44","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1080\/14728222.2016.1180368","volume":"20","author":"A Wagenfeld","year":"2016","unstructured":"Wagenfeld A, Saunders PT, Whitaker L, Critchley HO. Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert Opin Ther Targets. 2016;20(9):1045\u201354.","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"3539_CR45","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1056\/NEJMoa1103182","volume":"366","author":"J Donnez","year":"2012","unstructured":"Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366(5):409\u201320.","journal-title":"N Engl J Med"},{"key":"3539_CR46","doi-asserted-by":"crossref","unstructured":"Shipika. Ulipristal acetate versus placebo for fibroid treatment. Int J Adv Res. 2023;11:1348\u201354.","DOI":"10.21474\/IJAR01\/17351"},{"issue":"9","key":"3539_CR47","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1111\/jog.14802","volume":"47","author":"Y Osuga","year":"2021","unstructured":"Osuga Y, Nakano Y, Yamauchi Y, Murakawa H. Phase\u00a0III long-term study to evaluate the efficacy and safety of ulipristal acetate in Japanese patients with uterine fibroids. J Obstet Gynaecol Res. 2021;47(9):3269\u201378.","journal-title":"J Obstet Gynaecol Res"},{"key":"3539_CR48","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2147\/TCRM.S273358","volume":"21","author":"A Semmler","year":"2025","unstructured":"Semmler A, de Lange ME, Drenth JPH, et al. Hepatic safety considerations in the use of ulipristal acetate for symptomatic uterine fibroids. Ther Clin Risk Manag. 2025;21:367\u201382.","journal-title":"Ther Clin Risk Manag"},{"key":"3539_CR49","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ejogrb.2020.06.064","volume":"252","author":"S Rozenberg","year":"2020","unstructured":"Rozenberg S, Revercez P, Fastrez M, Vandromme J, Bucella D. Suspension of ulipristal acetate for uterine fibroids during ongoing EMA\u2019s review of liver injury risk: unfortunate timing during the Covid-19 pandemic! Eur J Obstet Gynecol Reprod Biol. 2020;252:300\u20132.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"3539_CR50","doi-asserted-by":"publisher","first-page":"101401","DOI":"10.1016\/j.jceh.2024.101401","volume":"14","author":"R Vuppalanchi","year":"2024","unstructured":"Vuppalanchi R, Chalasani N. Drug-induced liver injury from hormonal and non-hormonal therapies: insights from a large case series. J Clin Exp Hepatol. 2024;14(3):101401.","journal-title":"J Clin Exp Hepatol"},{"issue":"7","key":"3539_CR51","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jmig.2024.12.012","volume":"32","author":"M Dominoni","year":"2025","unstructured":"Dominoni M, Gardella B, Gritti A, Pasquali MF, Spinillo A. Conservative treatment of uterine myomas: a network meta-analysis of randomized controlled studies. J Minim Invasive Gynecol. 2025;32(7):583-91.e1.","journal-title":"J Minim Invasive Gynecol"},{"issue":"8","key":"3539_CR52","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/j.1471-0528.1999.tb08409.x","volume":"106","author":"F Chiaffarino","year":"1999","unstructured":"Chiaffarino F, Parazzini F, La Vecchia C, Marsico S, Surace M, Ricci E. Use of oral contraceptives and uterine fibroids: results from a case-control study. BJOG. 1999;106(8):857\u201360.","journal-title":"BJOG"},{"key":"3539_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cells12081117","author":"M Ali","year":"2023","unstructured":"Ali M, Ciebiera M, Vafaei S, et al. Progesterone signaling and uterine fibroid pathogenesis; molecular mechanisms and potential therapeutics. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12081117.","journal-title":"Cells"},{"issue":"2","key":"3539_CR54","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ejogrb.2013.09.010","volume":"171","author":"N Duhan","year":"2013","unstructured":"Duhan N, Madaan S, Sen J. Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women. Eur J Obstet Gynecol Reprod Biol. 2013;171(2):329\u201332.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"8","key":"3539_CR55","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jogc.2018.04.007","volume":"41","author":"L Fusca","year":"2019","unstructured":"Fusca L, Perelman I, Fergusson D, Boutet M, Chen I. The effectiveness of tranexamic acid at reducing blood loss and transfusion requirement for women undergoing myomectomy: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2019;41(8):1185-92.e1.","journal-title":"J Obstet Gynaecol Can"},{"issue":"6","key":"3539_CR56","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1097\/AOG.0000000000004401","volume":"137","author":"Management of Symptomatic Uterine Leiomyomas","year":"2021","unstructured":"Management of Symptomatic Uterine Leiomyomas. ACOG Practice Bulletin, Number 228. Obstet Gynecol. 2021;137(6):e100\u201315.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"3539_CR57","first-page":"Cd000154","volume":"2","author":"A Lethaby","year":"2019","unstructured":"Lethaby A, Wise MR, Weterings MA, Bofill Rodriguez M, Brown J. Combined hormonal contraceptives for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;2(2):Cd000154.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"3539_CR58","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ijgo.2010.08.009","volume":"112","author":"GH Sayed","year":"2011","unstructured":"Sayed GH, Zakherah MS, El-Nashar SA, Shaaban MM. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynaecol Obstet. 2011;112(2):126\u201330.","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"3539_CR59","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ijgo.12666","volume":"143","author":"MG Munro","year":"2018","unstructured":"Munro MG, Critchley HOD, Fraser IS. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143(3):393\u2013408.","journal-title":"Int J Gynaecol Obstet"},{"issue":"4","key":"3539_CR60","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/01.AOG.0000428646.67925.9a","volume":"121","author":"ACOG committee opinion no","year":"2013","unstructured":"ACOG committee opinion no. 557: Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol. 2013;121(4):891\u20136.","journal-title":"Obstet Gynecol"},{"issue":"1 Pt 1","key":"3539_CR61","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/0002-9378(95)90077-2","volume":"172","author":"MS Rein","year":"1995","unstructured":"Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol. 1995;172(1 Pt 1):14\u20138.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"3539_CR62","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4103\/0976-7800.98812","volume":"3","author":"RM Desai","year":"2012","unstructured":"Desai RM. Efficacy of levonorgestrel releasing intrauterine system for the treatment of menorrhagia due to benign uterine lesions in perimenopausal women. J Mid-life Health. 2012;3(1):20\u20133.","journal-title":"J Mid-life Health"},{"issue":"5","key":"3539_CR63","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.contraception.2012.07.018","volume":"86","author":"AM Kaunitz","year":"2012","unstructured":"Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, DeSanctis Y, Jensen J. Levonorgestrel-releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception. 2012;86(5):452\u20137.","journal-title":"Contraception"},{"key":"3539_CR64","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s13224-016-0865-3","volume":"66","author":"G Eralil","year":"2016","unstructured":"Eralil G. The effectiveness of levonorgestrel-releasing intrauterine system in the treatment of heavy menstrual bleeding. J Obstet Gynaecol India. 2016;66:505\u201312.","journal-title":"J Obstet Gynaecol India"},{"issue":"1","key":"3539_CR65","doi-asserted-by":"publisher","first-page":"62","DOI":"10.6118\/jmm.2018.24.1.62","volume":"24","author":"S Moradan","year":"2018","unstructured":"Moradan S. Gonadotropin-releasing hormone agonist plus aromatase inhibitor in the treatment of uterine leiomyoma in near menopause patient: a case series study. J Menopausal Med. 2018;24(1):62\u20136.","journal-title":"J Menopausal Med"},{"issue":"6","key":"3539_CR66","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.fertnstert.2012.08.053","volume":"98","author":"ME Pavone","year":"2012","unstructured":"Pavone ME, Bulun SE. Aromatase inhibitors for the treatment of endometriosis. Fertil Steril. 2012;98(6):1370\u20139.","journal-title":"Fertil Steril"},{"issue":"4","key":"3539_CR67","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1097\/AOG.0b013e3181f20177","volume":"116","author":"AS Lukes","year":"2010","unstructured":"Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116(4):865\u201375.","journal-title":"Obstet Gynecol"},{"issue":"7","key":"3539_CR68","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1111\/jog.14002","volume":"45","author":"MM Dolmans","year":"2019","unstructured":"Dolmans MM, Donnez J, Fellah L. Uterine fibroid management: today and tomorrow. J Obstet Gynaecol Res. 2019;45(7):1222\u20139.","journal-title":"J Obstet Gynaecol Res"},{"key":"3539_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010322","author":"A Tinelli","year":"2023","unstructured":"Tinelli A, Andji\u0107 M, Morciano A, et al. Uterine aging and reproduction: dealing with a puzzle biologic topic. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms25010322.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3539_CR70","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.fertnstert.2008.01.051","volume":"91","author":"EA Pritts","year":"2009","unstructured":"Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril. 2009;91(4):1215\u201323.","journal-title":"Fertil Steril"},{"issue":"10","key":"3539_CR71","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1055\/s-0040-1712446","volume":"42","author":"TD Corr\u00eaa","year":"2020","unstructured":"Corr\u00eaa TD, Caetano IM, Saraiva PHT, Noviello MB, Santos Filho AS. Use of GnRH analogues in the reduction of submucous fibroid for surgical hysteroscopy: a systematic review and meta-analysis. Rev Bras Ginecol Obstet. 2020;42(10):649\u201358.","journal-title":"Rev Bras Ginecol Obstet"},{"key":"3539_CR72","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.bpobgyn.2015.12.001","volume":"34","author":"LI Zepiridis","year":"2016","unstructured":"Zepiridis LI, Grimbizis GF, Tarlatzis BC. Infertility and uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2016;34:66\u201373.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"10356","key":"3539_CR73","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(22)01475-1","volume":"400","author":"J Donnez","year":"2022","unstructured":"Donnez J, Taylor HS, Stewart EA, et al. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase\u00a03 trials. Lancet. 2022;400(10356):896\u2013907.","journal-title":"Lancet"},{"issue":"10","key":"3539_CR74","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2174\/1871530321666201216164410","volume":"21","author":"NV Mohamad","year":"2021","unstructured":"Mohamad NV, Ima-Nirwana S, Chin KY. The skeletal effects of gonadotropin-releasing hormone antagonists: a concise review. Endocr Metab Immune Disord Drug Targets. 2021;21(10):1713\u201320.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"1","key":"3539_CR75","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jtha.2022.10.009","volume":"21","author":"HMG Wiegers","year":"2023","unstructured":"Wiegers HMG, Knijp J, van Es N, et al. Venous thromboembolism associated with estrogen-containing contraceptives versus any hormonal risk factor: a\u00a0comparison of recurrence rates. J Thromb Haemost. 2023;21(1):175\u20138.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"3539_CR76","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/TA.0000000000002061","volume":"86","author":"SP Myers","year":"2019","unstructured":"Myers SP, Kutcher ME, Rosengart MR, et al. Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism. J Trauma Acute Care Surg. 2019;86(1):20\u20137.","journal-title":"J Trauma Acute Care Surg"},{"key":"3539_CR77","doi-asserted-by":"publisher","first-page":"539365","DOI":"10.1155\/2012\/539365","volume":"2012","author":"D Simms-Stewart","year":"2012","unstructured":"Simms-Stewart D, Fletcher H. Counselling patients with uterine fibroids: a review of the management and complications. Obstet Gynecol Int. 2012;2012:539365.","journal-title":"Obstet Gynecol Int"},{"issue":"12","key":"3539_CR78","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1007\/s43032-024-01727-0","volume":"31","author":"D Hazimeh","year":"2024","unstructured":"Hazimeh D, Coco A, Casubhoy I, Segars J, Singh B. The annual economic burden of uterine fibroids in the United States (2010 versus 2022): a comparative cost-analysis. Reprod Sci. 2024;31(12):3743\u201356.","journal-title":"Reprod Sci"},{"issue":"1","key":"3539_CR79","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41467-017-00901-0","volume":"8","author":"C Chen","year":"2017","unstructured":"Chen C, Song X, Wei W, et al. The microbiota continuum along the female reproductive tract and its relation to uterine-related diseases. Nat Commun. 2017;8(1):875.","journal-title":"Nat Commun"},{"issue":"8","key":"3539_CR80","first-page":"djw029","volume":"108","author":"M Kwa","year":"2016","unstructured":"Kwa M, Plottel CS, Blaser MJ, Adams S. The intestinal microbiome and estrogen receptor-positive female breast cancer. J Natl Cancer Inst. 2016;108(8):djw029.","journal-title":"J Natl Cancer Inst"},{"key":"3539_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14103454","author":"A Tinelli","year":"2025","unstructured":"Tinelli A, Morciano A, Sparic R, et al. Artificial intelligence and uterine fibroids: a useful combination for diagnosis and treatment. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14103454.","journal-title":"J Clin Med"},{"issue":"1","key":"3539_CR82","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.xfre.2023.10.003","volume":"5","author":"M Barseghyan","year":"2024","unstructured":"Barseghyan M, Chae-Kim J, Catherino WH. The efficacy of medical management of leiomyoma-associated heavy menstrual bleeding: a mini review. F&S Reports. 2024;5(1):4\u20138.","journal-title":"F&S Reports"},{"issue":"6","key":"3539_CR83","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s13346-017-0423-2","volume":"7","author":"DR Friend","year":"2017","unstructured":"Friend DR. Drug delivery for the treatment of endometriosis and uterine fibroids. Drug Deliv Transl Res. 2017;7(6):829\u201339.","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"3539_CR84","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/humupd\/dmx032","volume":"24","author":"MS Islam","year":"2018","unstructured":"Islam MS, Ciavattini A, Petraglia F, Castellucci M, Ciarmela P. Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics. Hum Reprod Update. 2018;24(1):59\u201385.","journal-title":"Hum Reprod Update"},{"key":"3539_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065778","author":"Q Yang","year":"2023","unstructured":"Yang Q, Al-Hendy A. Update on the role and regulatory mechanism of extracellular matrix in the pathogenesis of uterine fibroids. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24065778.","journal-title":"Int J Mol Sci"},{"issue":"13","key":"3539_CR86","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3390\/cells13131091","volume":"13","author":"T-D Chuang","year":"2024","unstructured":"Chuang T-D, Ton N, Rysling S, Khorram O. In vivo effects of Bay\u00a011-7082 on fibroid growth and gene expression: a preclinical study. Cells. 2024;13(13):1091.","journal-title":"Cells"},{"issue":"2","key":"3539_CR87","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/REP-21-0087","volume":"162","author":"GW Kirschen","year":"2021","unstructured":"Kirschen GW, AlAshqar A, Miyashita-Ishiwata M, Reschke L, El Sabeh M, Borahay MA. Vascular biology of uterine fibroids: connecting fibroids and vascular disorders. Reproduction. 2021;162(2):R1-r18.","journal-title":"Reproduction"},{"key":"3539_CR88","doi-asserted-by":"publisher","DOI":"10.1080\/13625187.2025.2514746","author":"G Grandi","year":"2025","unstructured":"Grandi G, Barretta M, La Marca A. Sequential treatment with relugolix combination therapy in women with symptomatic uterine fibroids that were inadequately managed with 52\u2009mg levonorgestrel intrauterine system: the first report. Eur J Contracept Reprod Health Care. 2025. https:\/\/doi.org\/10.1080\/13625187.2025.2514746.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"1","key":"3539_CR89","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12943-017-0672-1","volume":"16","author":"N M\u00e4kinen","year":"2017","unstructured":"M\u00e4kinen N, K\u00e4mpj\u00e4rvi K, Frizzell N, B\u00fctzow R, Vahteristo P. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors. Mol Cancer. 2017;16(1):101.","journal-title":"Mol Cancer"},{"issue":"9","key":"3539_CR90","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1007\/s11010-021-04174-6","volume":"476","author":"M El Sabeh","year":"2021","unstructured":"El Sabeh M, Saha SK, Afrin S, Islam MS, Borahay MA. Wnt\/\u03b2-catenin signaling pathway in uterine leiomyoma: role in tumor biology and targeting opportunities. Mol Cell Biochem. 2021;476(9):3513\u201336.","journal-title":"Mol Cell Biochem"},{"issue":"12","key":"3539_CR91","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1007\/s43032-023-01289-7","volume":"30","author":"KK Vineetha","year":"2023","unstructured":"Vineetha KK, Bhat RG, Rao BK, Archana PR. The gut microbiota: a novel player in the pathogenesis of uterine fibroids. Reprod Sci. 2023;30(12):3443\u201355.","journal-title":"Reprod Sci"},{"key":"3539_CR92","doi-asserted-by":"publisher","first-page":"1177366","DOI":"10.3389\/fcimb.2023.1177366","volume":"13","author":"L Korczynska","year":"2023","unstructured":"Korczynska L, Zeber-Lubecka N, Zgliczynska M, et al. The role of microbiota in the pathophysiology of uterine fibroids - a systematic review. Front Cell Infect Microbiol. 2023;13:1177366.","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"3539_CR93","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4155\/tde.12.144","volume":"4","author":"H Ali","year":"2013","unstructured":"Ali H, Kilic G, Vincent K, Motamedi M, Rytting E. Nanomedicine for uterine leiomyoma therapy. Ther Deliv. 2013;4(2):161\u201375.","journal-title":"Ther Deliv"},{"issue":"9","key":"3539_CR94","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.3390\/molecules29092095","volume":"29","author":"BA Lulseged","year":"2024","unstructured":"Lulseged BA, Ramaiyer MS, Michel R, Saad EE, Ozpolat B, Borahay MA. The role of nanomedicine in benign gynecologic disorders. Molecules. 2024;29(9):2095.","journal-title":"Molecules"},{"issue":"3","key":"3539_CR95","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00404-023-07324-x","volume":"309","author":"A Tinelli","year":"2024","unstructured":"Tinelli A, Panese G, Licchelli M, Morciano A, Pecorella G, Gambioli R. The impact of epigallocatechin gallate, vitamin\u00a0D, and D-chiro-inositol on early surgical outcomes of laparoscopic myomectomy: a pilot study. Arch Gynecol Obstet. 2024;309(3):1021\u20136.","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"3539_CR96","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/09513590.2021.1991909","volume":"38","author":"G Grandi","year":"2022","unstructured":"Grandi G, Del Savio MC, Melotti C, Feliciello L, Facchinetti F. Vitamin\u00a0D and green tea extracts for the treatment of uterine fibroids in late reproductive life: a pilot, prospective, daily-diary based study. Gynecol Endocrinol. 2022;38(1):63\u20137.","journal-title":"Gynecol Endocrinol"},{"issue":"3","key":"3539_CR97","doi-asserted-by":"publisher","first-page":"483","DOI":"10.17305\/bb.2025.12952","volume":"26","author":"Y Onaran","year":"2025","unstructured":"Onaran Y, Goktas E, \u00d6zt\u00fcrk BA, Kahyaoglu S, Akkaya H. Vitamin\u00a0D deficiency and uterine leiomyoma in unexplained infertility. Biomol Biomed. 2025;26(3):483\u20139.","journal-title":"Biomol Biomed"},{"issue":"1","key":"3539_CR98","first-page":"438","volume":"25","author":"R Gambioli","year":"2021","unstructured":"Gambioli R, Forte G, Aragona C, Bevilacqua A, Bizzarri M, Unfer V. The use of D-chiro-inositol in clinical practice. Eur Rev Med Pharmacol Sci. 2021;25(1):438\u201346.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"3539_CR99","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3390\/nu16040559","volume":"16","author":"M W\u0142odarczyk","year":"2024","unstructured":"W\u0142odarczyk M, Ciebiera M, Nowicka G, \u0141ozi\u0144ski T, Ali M, Al-Hendy A. Epigallocatechin gallate for the treatment of benign and malignant gynecological diseases\u2014focus on epigenetic mechanisms. Nutrients. 2024;16(4):559.","journal-title":"Nutrients"},{"issue":"5","key":"3539_CR100","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.fertnstert.2009.08.065","volume":"94","author":"D Zhang","year":"2010","unstructured":"Zhang D, Al-Hendy M, Richard-Davis G, Montgomery-Rice V, Rajaratnam V, Al-Hendy A. Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells. Fertil Steril. 2010;94(5):1887\u201393.","journal-title":"Fertil Steril"},{"key":"3539_CR101","doi-asserted-by":"publisher","first-page":"118345","DOI":"10.1016\/j.biopha.2025.118345","volume":"189","author":"M de Mezer","year":"2025","unstructured":"de Mezer M, Markowska A, Pietras J, et al. The role of epigallocatechin gallate (EGCG) in uterine myomas. Biomed Pharmacother. 2025;189:118345.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"3539_CR102","doi-asserted-by":"publisher","first-page":"289.e1","DOI":"10.1016\/j.ajog.2009.10.885","volume":"202","author":"D Zhang","year":"2010","unstructured":"Zhang D, Al-Hendy M, Richard-Davis G, et al. Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am J Obstet Gynecol. 2010;202(3):289.e1-9.","journal-title":"Am J Obstet Gynecol"},{"key":"3539_CR103","first-page":"477","volume":"5","author":"E Roshdy","year":"2013","unstructured":"Roshdy E, Rajaratnam V, Maitra S, Sabry M, Allah AS, Al-Hendy A. Treatment of symptomatic uterine fibroids with green tea extract: a pilot randomized controlled clinical study. Int J Womens Health. 2013;5:477\u201386.","journal-title":"Int J Womens Health"},{"issue":"1","key":"3539_CR104","doi-asserted-by":"publisher","first-page":"e078989","DOI":"10.1136\/bmjopen-2023-078989","volume":"14","author":"A Al-Hendy","year":"2024","unstructured":"Al-Hendy A, Segars JH, Taylor HS, et al. Fibroids and unexplained infertility treatment with epigallocatechin gallate: a natural compound in green tea (FRIEND) \u2013 protocol for a randomised placebo-controlled US multicentre clinical trial of EGCG to improve fertility in women with uterine fibroids. BMJ Open. 2024;14(1):e078989.","journal-title":"BMJ Open"},{"issue":"4","key":"3539_CR105","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00228-008-0610-7","volume":"65","author":"G Mazzanti","year":"2009","unstructured":"Mazzanti G, Menniti-Ippolito F, Moro PA, et al. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol. 2009;65(4):331\u201341.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03539-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03539-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03539-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:20:53Z","timestamp":1778581253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03539-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":105,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["3539"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03539-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors, Giovanni Pecorella, Andrea Morciano, Radmila Sparic, Safak Hatirnaz, Mykhailo Medvediev, Antonio Malvasi, Gianluca Raffaello Damiani, Andrea Tinelli, declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Consent for the processing of data and material related to patient hospitalization, including video of the procedure or diagnostic tests, was obtained. This confirmed the anonymous use of patient data, diagnostic tests, and procedures for publication purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}